Hemab Announces Positive Phase 2 Data for Sutacimig
Slice of Healthcare Team
12/09/2025
Key highlights
- 87% reduction in annualized treated bleeding rates.
- Clinically meaningful efficacy shown across multiple bleed types.
- Plans to begin Phase 3 registration study in 2026.
Source: PR Newswire
Notable Quotes
“ These Phase 2 results represent transformational potential for people living with Glanzmann thrombasthenia, who have waited a lifetime for a modern prophylactic treatment. ”
Benny Sorensen, MD, PhD, CEO at Hemab
“ What stands out in these results is the reduction of the most severe bleeding events requiring intensive interventions. ”
Paul Saultier, MD, PhD, Head of the French Platelet Reference Center at APHM Hospital de la Timone
Why this matters
The announcement signifies a pivotal advancement in the treatment of Glanzmann thrombasthenia, a disease with significant unmet need. The promising results from the Phase 2 study pave the way for potentially groundbreaking changes in patient care and treatment strategies. This development is particularly significant for the healthcare sector.
Expert Insights
Share Your Expert Insights
Have relevant experience or professional perspective? Add your thoughtful insights to this article.
